

CSD/BSE&NSE/2023-24
February 24, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) – Grant of Stock Options by the Nomination & Remuneration Committee of the Company

.....

We wish to inform you that the Nomination & Remuneration Committee of the Suven Pharmaceuticals Limited (“Company”), considered and approved the grant of 65,94,308 Stock Options at its meeting held on 24th February, 2024 under the Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023 (“ESOP 2023 / Plan”) to eligible employees of the Company.

In this connection, disclosure as required under Regulation 30 of SEBI LODR read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is given below:

Brief details of options granted	65,94,308 Stock Options have been granted to the eligible employees of the Company.
Whether the scheme is in terms of SEBI (SBEB SE) Regulations, 2021	The Scheme – “Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023” – has been formulated in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (“SEBI SBEB SE”).
Total number of shares covered by these Options	65,94,308 Equity shares of Rs. 1.00 each of the Company. Each stock option carries the right to apply for and be allotted 1 (one) equity share of face value of Rs. 1.00 each of the Company.
Pricing formula	As per the ESOP 2023
Options vested/vesting Period	All the options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective

Suven Pharmaceuticals Limited

	employees. The Nomination and Remuneration Committee may at its discretion, but subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.
Time within which option may be exercised	The exercise period shall be upto 3 (three) years from the date of vesting of Options.
Options exercised	Nil
Money realized by exercise of options	Nil
The total number of shares arising as a result of exercise of option	Nil
Options lapsed	Nil
Variation of terms of options	The Board or Nomination and Remuneration Committee may, if it deems necessary, modify, change, vary, amend, suspend or terminate the ESOP 2023, subject to compliance with the applicable laws and regulations.
Brief details of significant terms	Options granted under plan shall vest not earlier than minimum period of 1 (One) year and not later than maximum period of 10 (Ten) years from the date of grant.
Subsequent changes or cancellation or exercise of such options	NA
Diluted earnings per share pursuant to issue of equity shares on exercise of options	NA

This is for your information and record.

Thanking you,
 Yours faithfully,
 For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao
 Company Secretary

Suven Pharmaceuticals Limited